Cellectar Biosciences (CLRB) announced the signing of a strategic supply agreement with NorthStar Medical Radioisotopes, LLC, for the procurement of NorthStar’s non-carrier added Ac-225. The Company’s CLR 121225 development program combines its proprietary Phospholipid Ether, PLE, delivery platform and actinium 225 for the treatment of solid tumors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks